EGFR and lung cancer: However, despite an almost universal presence of EGFR in NSCLC tumors, the therapeutic inhibition of EGFR by gefitinib and erlotinib results in significant tumor regression in only 10–20% of patients, again indicating the variation in the molecular pathogenesis of the different types of lung cancer.